Key result
KCNC2 pathogenic variants were identified in 18 patients with various forms of epilepsy, establishing KCNC2 as a novel causative gene for epilepsy.
Why the study?
The study was conducted to analyze the clinical phenotype, genetic background, and biophysical function of disease-associated Kv3.2 variants encoded by KCNC2.
Observational (n=18)
Yes
KCNC2 is implicated as a novel causative gene for epilepsy, highlighting the role of KV3.2 in regulating brain excitability.
Answers are grounded in this paper and cite their sources.
KCNC2 variants expand the genetic spectrum of epilepsy; leaves open whether functional effects guide targeted therapies.
Background and Objectives KCNC2 encodes Kv3.2, a member of the Shaw-related (Kv3) voltage-gated potassium channel subfamily, which is important for sustained high-frequency firing and optimized energy efficiency of action potentials in the brain. The objective of this study was to analyze the clinical phenotype, genetic background, and biophysical function of disease-associated Kv3.2 variants. Methods Individuals with KCNC2 variants detected by exome sequencing were selected for clinical, further genetic, and functional analysis. Cases were referred through clinical and research collaborations. Selected de novo variants were examined electrophysiologically in Xenopus laevis oocytes. Results We identified novel KCNC2 variants in 18 patients with various forms of epilepsy, including genetic generalized epilepsy (GGE), developmental and epileptic encephalopathy (DEE) including early-onset absence epilepsy, focal epilepsy, and myoclonic-atonic epilepsy. Of the 18 variants, 10 were de novo and 8 were classified as modifying variants. Eight drug-responsive patients became seizure-free using valproic acid as monotherapy or in combination, including severe DEE cases. Functional analysis of 4 variants demonstrated gain of function in 3 severely affected DEE cases and loss of function in 1 case with a milder phenotype (GGE) as the underlying pathomechanisms. Discussion These findings implicate KCNC2 as a novel causative gene for epilepsy and emphasize the critical role of KV3.2 in the regulation of brain excitability.
No takes yet. Share an insight, caveat, or question.
Schwarz et al. (2022) conducted an observational in Epilepsy (n=18). KCNC2 pathogenic variants was evaluated on Clinical phenotype, genetic background, and biophysical function. KCNC2 pathogenic variants were identified in 18 patients with various forms of epilepsy, establishing KCNC2 as a novel causative gene for epilepsy.
Synapse has enriched 10 related papers. Consider them for comparative context: